Try our beta test site
Trial record 3 of 13 for:    pegph20

PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer (HALO-IST)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Scripps Health
Sponsor:
Information provided by (Responsible Party):
Darren Sigal, MD, Scripps Health
ClinicalTrials.gov Identifier:
NCT02910882
First received: August 12, 2016
Last updated: January 18, 2017
Last verified: January 2017
  Purpose
This is a single arm phase II trial assessing the potential activity of combination PEGPH20 plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic adenocarcinoma.

Condition Intervention Phase
Pancreatic Adenocarcinoma Non-resectable
Drug: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Drug: Gemcitabine
Radiation: Radiation
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase II Study Combining PEGPH20 With Concurrent Gemcitabine and Radiotherapy in Patients With Localized, Unresectable Pancreatic Adenocarcinoma

Resource links provided by NLM:


Further study details as provided by Scripps Health:

Primary Outcome Measures:
  • Number of Participants with Treatment Related Adverse Events (AEs) [ Time Frame: Up to 8 Weeks After the End of Treatment ]

    Adverse events will be assessed weekly, from Day1 Treatment through up to 8 weeks after the end of treatment. Safety will be assessed during the study by evaluation of AEs, clinical safety laboratory tests (hematology, blood chemistry (including C-reactive protein [CRP]), coagulation, urinalysis, and PEGPH20 immunogenicity), vital signs, 12-lead ECGs, and physical examinations.

    The severity of AEs will be graded by Investigators using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03



Secondary Outcome Measures:
  • Overall Tumor Response Rate [ Time Frame: Change from Baseline through 8 Weeks After End of Radiation Therapy ]
    CT Chest/Abdomen/Pelvis will be completed at End of Study Visit. End of Study visit will be done 6-8 weeks after the last day of radiotherapy. The evaluation of overall lesion response will be a composite of the target lesion response, non-target lesion response and presence of new lesions, per RECIST 1.1 criteria.

  • Conversion to Resectability Rate [ Time Frame: Up to 8 Weeks After End of Radiation Therapy ]
    Number of enrolled subjects completing at least 2 weeks of PEGPH20 plus concurrent gemcitabine and radiotherapy who meet institutional surgical criteria for surgical resectability, as determined by End of Study CT imaging. End of Study CT imaging will be done up to 8 weeks after the end of radiation therapy.

  • Carcinoembryonic Antigen (CEA) Response [ Time Frame: Change from Day 1 through 8 Weeks After End of Treatment ]
    Change in CEA serum levels from Day 1 through 8 weeks after end of treatment will be assessed.

  • CA 19-9 Response [ Time Frame: Change from Day 1 through 8 Weeks After End of Treatment ]
    Change in CA 19-9 serum levels from Day 1 through 8 weeks after end of treatment will be assessed.

  • Determine the Maximum or Peak Plasma PEGPH20 Concentration (cmax) at End of Infusion [ Time Frame: At Specific Timepoints from Day 1 through Day 39 During Treatment ]

    Maximum Plasma PEGPH20 concentration (cmax) will be analyzed in all patients, at the following time points:

    Day 1: Pre-Dose; Day 1 Post-Dose @ 1hr, 2hr, 6hr; Day 2 (24Hr Post Dose); Day 3 (48Hr Post Dose); Day 4 (72Hr Post Dose); Day 8: Pre-Dose; Day 9 (24Hr Post Dose); Day 10 (48Hr Post Dose); Day 11 (72 Hr Post Dose); Day 36: Pre-Dose; Day 37 (24 Hr Post Dose); Day 38 (48Hr Post Dose); Day 39 (72 Hr Post Dose);

    Pharmacokinetic (PK) data will analyzed by non-compartmental analysis (NCA).


  • Determine Plasma PEGPH20 Area Under the Curve (AUC) After Day 1 PEGPH20 Infusion [ Time Frame: At Specific Timepoints from Day 1 through Day 39 During Treatment ]

    Plasma PEGPH20 Area Under the Curve (AUC) will be analyzed in all patients, at the following time points:

    Day 1: Pre-Dose; Day 1 Post-Dose @ 1hr, 2hr, 6hr; Day 2 (24Hr Post Dose); Day 3 (48Hr Post Dose); Day 4 (72Hr Post Dose); Day 8: Pre-Dose; Day 9 (24Hr Post Dose); Day 10 (48Hr Post Dose); Day 11 (72 Hr Post Dose); Day 36: Pre-Dose; Day 37 (24 Hr Post Dose); Day 38 (48Hr Post Dose); Day 39 (72 Hr Post Dose);

    Pharmacokinetic (PK) data will analyzed by non-compartmental analysis (NCA).


  • Determine the Maximum or Peak Plasma Hyaluronan Concentration (cmax) After First Dose of PEGPH20 [ Time Frame: At Specific Timepoints from Day 1 through Day 39 During Treatment ]

    Plasma Hyaluronan (HA) will be analyzed in all patients, at the following time points:

    Day 1: Pre-Dose; Day 2 (24Hr Post Dose); Day 3 (48Hr Post Dose); Day 4 (72Hr Post Dose); Day 8: Pre-Dose; Day 9 (24Hr Post Dose); Day 10 (48Hr Post Dose); Day 11 (72 Hr Post Dose); Day 36: Pre-Dose; Day 37(24 Hr Post Dose); Day 38(48Hr Post Dose); Day 39 (72 Hr Post Dose);

    Hyaluronan pharmacodynamic (PD) data will analyzed by non-compartmental analysis (NCA).


  • Determine Plasma Hyaluronan Area Under Effect Curve (AUEC) After First Dose of PEGPH20 [ Time Frame: At Specific Timepoints from Day 1 through Day 39 During Treatment ]

    Plasma Hyaluronan (HA) will be analyzed in all patients, at the following time points:

    Day 1: Pre-Dose; Day 2 (24Hr Post Dose); Day 3 (48Hr Post Dose); Day 4 (72Hr Post Dose); Day 8: Pre-Dose; Day 9 (24Hr Post Dose); Day 10 (48Hr Post Dose); Day 11 (72 Hr Post Dose); Day 36: Pre-Dose; Day 37(24 Hr Post Dose); Day 38(48Hr Post Dose); Day 39 (72 Hr Post Dose);

    Hyaluronan pharmacodynamic (PD) data will analyzed by non-compartmental analysis (NCA).



Estimated Enrollment: 10
Actual Study Start Date: January 3, 2017
Estimated Study Completion Date: December 1, 2018
Estimated Primary Completion Date: June 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Arm

Cohort I (PEGPH20 Dose Escalation + Gemcitabine and Concurrent Radiotherapy), First 3 Patients:

An abbreviated sequential dose escalation schema for the first 3 patients (each subsequent patient will be accrued only after no dose limiting toxicities are found in the first 2 weeks of concurrent therapy for the previous patient).

Intravenous (IV) PEGPH20, per dose escalation guidelines for first 3 patients; Intravenous (IV) Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);

Cohort II (PEGPH20 + Gemcitabine and Concurrent Radiotherapy), Patients 4 - 10:

IV PEGPH20, per dosing level determined in dose escalation (Cohort I); IV Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);

Drug: PEGylated Recombinant Human Hyaluronidase (PEGPH20)

PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:

Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.

PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.

Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy.

Other Name: PEGylated rHuPH20
Drug: Gemcitabine

Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.

Dosing Schedule: Weekly, beginning Day #2, per standard regimen.

Other Name: Gemzar
Radiation: Radiation
Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.

Detailed Description:
This is a pilot trial evaluating the safety and potential efficacy of PEGylated Recombinant Human Hyaluronidase (PEGPH20) plus concurrent Gemcitabine and radiotherapy. Recognizing that PEGPH20 has not been previously delivered with radiotherapy but is unlikely to contribute to increased toxicities, this trial will have an abbreviated sequential dose escalation schema for the first three patients. PEGPH20 will be given twice per week for the first 28 days and then weekly for another 2 weeks during radiotherapy. Gemcitabine will be delivered weekly at the first day of radiotherapy and continued weekly, per published literature. Patients will remain on study for three months. The duration of active treatment with PEGPH20 and Gemcitabine plus radiotherapy will continue for 5-6 weeks. Efficacy outcome will occur 6-8 weeks after the completion of radiotherapy.
  Eligibility

Ages Eligible for Study:   up to 90 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects must satisfy all the following inclusion criteria to be enrolled in the study:

  1. Signed, written Institutional Review Board/Ethics Committee-approved Informed Consent Form;
  2. For men and women of reproductive potential, agreement to use an effective contraceptive method from the time of screening and throughout their time on study. Effective contraceptive methods consist of prior sterilization, intra-uterine device, oral or injectable contraceptives, and/or barrier methods. Abstinence alone is not considered an adequate contraceptive measure for the purposes of this study;
  3. Patients with previously untreated localized, unresectable histologically confirmed pancreatic adenocarcinoma (unresectable will be defined as locally advanced disease or when patients cannot have or refuse surgery);
  4. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L;
  5. Platelets ≥ 100 x 109/L;
  6. Hgb ≥ 9 g/dL;
  7. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 x [Upper Limit of Normal (ULN)];
  8. Bilirubin ≤ 1.5 x ULN;
  9. GFR ≥ 30 mL/min;
  10. Patient has no clinically significant abnormalities in urinalysis results;
  11. Patient has acceptable coagulation status as indicated by a Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) within 15% of normal limits;
  12. Eastern Cooperative Oncology Group (ECOG) ≤ 2

Exclusion Criteria:

Subjects are ineligible for enrollment if they meet any of the following exclusion criteria:

  1. Clinical evidence of deep vein thrombosis (DVT), pulmonary embolism (PE) or other known thromboembolic (TE) event present during the screening period;
  2. Any prior history of cerebrovascular accident, transient ischemic attack, or pre-existing carotid artery disease.
  3. Known allergy to hyaluronidase;
  4. Current use of megestrol acetate (use within 10 days of Day 1);
  5. Contraindication to heparin including prior heparin induced thrombocytopenia (HIT), recent CNS bleed; intracranial or spinal lesion at high risk for bleeding; severe platelet dysfunction; recent major operation at high risk for bleeding; underlying hemorrhagic coagulopathy; high risk for falls; potential need for spinal anesthesia/lumbar puncture; active bleeding;
  6. Women currently pregnant or breastfeeding;
  7. Intolerance to dexamethasone;
  8. Inability to comply with study and follow-up procedures as judged by the Investigator;
  9. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy;
  10. Patient has known infection with HIV, hepatitis B, or hepatitis C;
  11. Patient has a history of allergy or hypersensitivity to any of the agents they are supposed to receive (or to any of the excipients for those agents);
  12. Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug, these can include New York Heart Association Functional Class ≥ 3, myocardial infarction within the past 12 months before screening, pre-existing atrial fibrillation, symptomatic COPD.
  13. Patient is unwilling or unable to comply with study procedures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02910882

Contacts
Contact: Lori Tijerina, RN 858-554-9217 Tijerina.Lorraine@scrippshealth.org
Contact: Gail Moore, RN, CCRC 858-554-8365 moore.gail@scrippshealth.org

Locations
United States, California
Scripps Cancer Center Recruiting
La Jolla, California, United States, 92037
Contact: Lori Tijerina, RN    858-554-9217    tijerina.lorraine@scrippshealth.org   
Contact: Gail Moore, RN    858-554-8365    moore.gail@scrippshealth.org   
Principal Investigator: Darren Sigal, MD         
Sub-Investigator: Michael Kosty, MD         
Sub-Investigator: James Mason, MD         
Sub-Investigator: Sonia Ali, MD         
Sponsors and Collaborators
Scripps Health
Investigators
Principal Investigator: Darren S Sigal, MD Scripps Health/Scripps Clinic
  More Information

Publications:
Hingorani S, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotskyet EM, et al. Final Results of a Phase 1b Study of Gemcitabine Plus PEGPH20 in Patients With Stage IV Previously Untreated Pancreatic Cancer. ASCO 2015 Gastrointestinal Cancers Symposium, Poster Abstract 359.
Li X, Jiang P, Symons R, et al. Pegylated human recombinant hyaluronidase PH20 reduces solid tumor hypoxia [abstract]. Cancer Res 2012; 72(8 Suppl): Abstract 3796.
Li X. PEGylated human recombinant hyaluronidase (PEGPH20) removes peritumoral hyaluronan and increases the efficacy of chemotherapy and radiotherapy in an experimental brain metastasis model [abstract]. Cancer Res 2009; 69 (9 Suppl): Abstract 262.

Responsible Party: Darren Sigal, MD, Principal Investigator, Scripps Health
ClinicalTrials.gov Identifier: NCT02910882     History of Changes
Other Study ID Numbers: PEGPH20-GEM-XRT
Study First Received: August 12, 2016
Last Updated: January 18, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Scripps Health:
Pancreas Cancer
Unresectable
Chemoradiation
PEGPH20

Additional relevant MeSH terms:
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gemcitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on March 27, 2017